Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035415 | 0.90 | PPARG (0.40) | PTGER4PTGER3PTGER2ALDH1A1GAA | |
| SCHEMBL6035639 | 0.87 | PTGER1 (0.33) | PTGER4PTGER3PTGER2PTGER1PPARG | |
| SCHEMBL6036258 | 0.86 | SMN1; SMN2 (0.37) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL6253930 | 0.86 | PTPN1 (0.41) | ALDH1A1GAA | |
| SCHEMBL6035756 | 0.83 | PTGER4 (0.35) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL6035698 | 0.83 | ABCB1 (0.38) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL1633509 | 0.81 | PPARG (0.33) | PPARDPPARG | |
| SCHEMBL6034696 | 0.80 | PPARG (0.32) | PPARG | |
| SCHEMBL1634152 | 0.79 | PPARG (0.43) | ALDH1A1PPARDPPARG | |
| SCHEMBL6035821 | 0.79 | SMN1; SMN2 (0.36) | PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | claimed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | claimed |
| US-7932289-B2 | Remedy for diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080319077-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-12-25 | — | — | US | disclosed |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319077-A1 | Remedy for Diabetes | GPR119, GLP1R, GPR65 | PTGER4 1323/4885PTGER3 1683/4885PTGER2 1913/4885 |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PTGER4 2147/4885PTGER3 4074/4885PTGER2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.